{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T20:50:25Z","timestamp":1762980625719,"version":"build-2065373602"},"reference-count":31,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,3,1]],"date-time":"2019-03-01T00:00:00Z","timestamp":1551398400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"JSPS KAKENHI","award":["17K11145"],"award-info":[{"award-number":["17K11145"]}]},{"DOI":"10.13039\/100007449","name":"Takeda Science Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100007449","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Shin-Nihon Foundation of Advanced Medical Research"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Urologic Oncology: Seminars and Original Investigations"],"published-print":{"date-parts":[[2019,3]]},"DOI":"10.1016\/j.urolonc.2018.10.020","type":"journal-article","created":{"date-parts":[[2018,11,13]],"date-time":"2018-11-13T09:49:33Z","timestamp":1542102573000},"page":"180.e19-180.e24","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"title":["Serum testosterone level as possible predictive marker in androgen receptor axis-targeting agents and taxane chemotherapies for castration-resistant prostate cancer"],"prefix":"10.1016","volume":"37","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3306-4858","authenticated-orcid":false,"given":"Masaki","family":"Shiota","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eiji","family":"Kashiwagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomohiko","family":"Murakami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ario","family":"Takeuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenjiro","family":"Imada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Junichi","family":"Inokuchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsunori","family":"Tatsugami","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatoshi","family":"Eto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.urolonc.2018.10.020_bib0001","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1111\/iju.13091","article-title":"Current status of primary pharmacotherapy and future perspectives toward upfront therapy for metastatic hormone-sensitive prostate cancer","volume":"23","author":"Shiota","year":"2016","journal-title":"Int J Urol"},{"key":"10.1016\/j.urolonc.2018.10.020_bib0002","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1056\/NEJMoa1704174","article-title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer","volume":"377","author":"Fizazi","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2018.10.020_bib0003","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy","volume":"377","author":"James","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.urolonc.2018.10.020_bib0004","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/iju.12907","article-title":"Novel agents for castration-resistant prostate cancer: early experience and beyond","volume":"23","author":"Fujimoto","year":"2016","journal-title":"Int J Urol"},{"key":"10.1016\/j.urolonc.2018.10.020_bib0005","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1016\/j.ejca.2015.06.128","article-title":"Prior long response to androgen deprivation predicts response to next-generation androgen receptor axis targeted drugs in castration resistant prostate cancer","volume":"51","author":"Loriot","year":"2015","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.urolonc.2018.10.020_bib0006","series-title":"ASCO Annual Meeting","article-title":"Efficacy of docetaxel chemotherapy in metastatic prostate cancer (mPC) patients (pts) experiencing early castration resistance (CR)","author":"Huillard","year":"2013"},{"key":"10.1016\/j.urolonc.2018.10.020_bib0007","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1016\/j.eururo.2017.06.002","article-title":"Management of patients with advanced prostate cancer: the report of the advanced prostate cancer consensus conference APCCC 2017","volume":"73","author":"Gillessen","year":"2018","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2018.10.020_bib0008","unstructured":"Cucchiara V, Cooperberg MR, Dall'Era M, et al. Genomic markers in prostate cancer decision making. Eur Urol [Epub ahead of print]"},{"key":"10.1016\/j.urolonc.2018.10.020_bib0009","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.critrevonc.2017.11.007","article-title":"Biomarkers in prostate cancer\u2013current clinical utility and future perspectives","volume":"120","author":"Kretschmer","year":"2017","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.urolonc.2018.10.020_bib0010","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nm.4045","article-title":"Divergent clonal evolution of castration-resistant neuroendocrine prostate cancer","volume":"22","author":"Beltran","year":"2016","journal-title":"Nat Med"},{"key":"10.1016\/j.urolonc.2018.10.020_bib0011","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1001\/jama.1991.03460050072023","article-title":"Independent prognostic factors in patients with metastatic (stage D2) prostate cancer. The Zoladex Study Group","volume":"265","author":"Chodak","year":"1991","journal-title":"JAMA"},{"key":"10.1016\/j.urolonc.2018.10.020_bib0012","first-page":"6925","article-title":"Prognostic impact of serum testosterone and body mass index before androgen-deprivation therapy in metastatic prostate cancer","volume":"35","author":"Shiota","year":"2015","journal-title":"Anticancer Res"},{"key":"10.1016\/j.urolonc.2018.10.020_bib0013","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1200\/JCO.2014.58.2973","article-title":"Nadir testosterone within first year of androgen-deprivation therapy (ADT) predicts for time to castration-resistant progression: a secondary analysis of the PR-7 trial of intermittent versus continuous ADT","volume":"33","author":"Klotz","year":"2015","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2018.10.020_bib0014","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1038\/pcan.2016.2","article-title":"The prognostic impact of serum testosterone during androgen-deprivation therapy in patients with metastatic prostate cancer and the SRD5A2 polymorphism","volume":"19","author":"Shiota","year":"2016","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.urolonc.2018.10.020_bib0015","doi-asserted-by":"crossref","first-page":"5033","DOI":"10.1158\/0008-5472.CAN-06-3332","article-title":"Intraprostatic androgens and androgen-regulated gene expression persist after testosterone suppression: therapeutic implications for castration-resistant prostate cancer","volume":"67","author":"Mostaghel","year":"2007","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2018.10.020_bib0016","doi-asserted-by":"crossref","first-page":"6407","DOI":"10.1158\/0008-5472.CAN-07-5997","article-title":"Androgen levels increase by intratumoral de novo steroidogenesis during progression of castration-resistant prostate cancer","volume":"68","author":"Locke","year":"2008","journal-title":"Cancer Res"},{"key":"10.1016\/j.urolonc.2018.10.020_bib0017","doi-asserted-by":"crossref","first-page":"2791","DOI":"10.1200\/JCO.2012.45.4595","article-title":"Serum androgens as prognostic biomarkers in castration-resistant prostate cancer: results from an analysis of a randomized phase III trial","volume":"31","author":"Ryan","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2018.10.020_bib0018","series-title":"TNM classification of malignant tumors","first-page":"170","article-title":"Prostate","year":"1997"},{"key":"10.1016\/j.urolonc.2018.10.020_bib0019","doi-asserted-by":"crossref","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","article-title":"Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the prostate cancer clinical trials working group","volume":"26","author":"Scher","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.urolonc.2018.10.020_bib0020","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/j.juro.2017.09.076","article-title":"The association of polymorphisms in the gene encoding gonadotropin releasing hormone with serum testosterone level during androgen deprivation therapy and prognosis in metastatic prostate cancer","volume":"199","author":"Shiota","year":"2018","journal-title":"J Urol"},{"key":"10.1016\/j.urolonc.2018.10.020_bib0021","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1093\/jjco\/hyq193","article-title":"Serum testosterone level to predict the efficacy of sequential use of antiandrogens as second-line treatment following androgen deprivation monotherapy in patients with castration-resistant prostate cancer","volume":"41","author":"Hashimoto","year":"2011","journal-title":"Jpn J Clin Oncol"},{"key":"10.1016\/j.urolonc.2018.10.020_bib0022","doi-asserted-by":"crossref","first-page":"2201","DOI":"10.1038\/bjc.2014.189","article-title":"Prognostic and predictive value of plasma testosterone levels in patients receiving first-line chemotherapy for metastatic castrate-resistant prostate cancer","volume":"110","author":"de Lia\u00f1o","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.urolonc.2018.10.020_bib0023","doi-asserted-by":"crossref","first-page":"E500","DOI":"10.1111\/j.1464-410X.2012.11190.x","article-title":"Incomplete testosterone suppression with luteinizing hormone-releasing hormone agonists: does it happen and does it matter?","volume":"110","author":"Pickles","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.urolonc.2018.10.020_bib0024","first-page":"349","article-title":"An exploratory analysis of the association between levels of hormones implied in steroid biosynthesis and activity of abiraterone in patients with metastatic castration-resistant prostate cancer","volume":"69","author":"Bertaglia","year":"2017","journal-title":"Minerva Urol Nefrol"},{"key":"10.1016\/j.urolonc.2018.10.020_bib0025","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1038\/pcan.2008.36","article-title":"The relationship of body mass index and serum testosterone with disease outcomes in men with castration-resistant metastatic prostate cancer","volume":"12","author":"Armstrong","year":"2009","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.urolonc.2018.10.020_bib0026","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.eururo.2014.05.005","article-title":"Molecular characterization of enzalutamide-treated bone metastatic castration-resistant prostate cancer","volume":"67","author":"Efstathiou","year":"2015","journal-title":"Eur Urol"},{"key":"10.1016\/j.urolonc.2018.10.020_bib0027","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1038\/pcan.2014.8","article-title":"Androgen dynamics and serum PSA in patients treated with abiraterone acetate","volume":"17","author":"Ryan","year":"2014","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"10.1016\/j.urolonc.2018.10.020_bib0028","doi-asserted-by":"crossref","first-page":"1336","DOI":"10.1002\/pros.22681","article-title":"Interaction between docetaxel resistance and castration resistance in prostate cancer: implications of Twist1, YB-1, and androgen receptor","volume":"73","author":"Shiota","year":"2013","journal-title":"Prostate"},{"key":"10.1016\/j.urolonc.2018.10.020_bib0029","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ebiom.2017.12.024","article-title":"Testosterone diminishes cabazitaxel efficacy and intratumoral accumulation in a prostate cancer xenograft model","volume":"27","author":"Mout","year":"2018","journal-title":"EBioMedicine"},{"key":"10.1016\/j.urolonc.2018.10.020_bib0030","doi-asserted-by":"crossref","first-page":"22","DOI":"10.3892\/ol.2016.5392","article-title":"Role of free testosterone levels in patients with metastatic castration-resistant prostate cancer receiving second-line therapy","volume":"13","author":"von Klot","year":"2017","journal-title":"Oncol Lett"},{"key":"10.1016\/j.urolonc.2018.10.020_bib0031","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1186\/1471-2407-14-717","article-title":"High testosterone levels in prostate tissue obtained by needle biopsy correlate with poor-prognosis factors in prostate cancer patients","volume":"14","author":"Miyoshi","year":"2014","journal-title":"BMC Cancer"}],"container-title":["Urologic Oncology: Seminars and Original Investigations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143918304046?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1078143918304046?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T10:14:21Z","timestamp":1761041661000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1078143918304046"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3]]},"references-count":31,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2019,3]]}},"alternative-id":["S1078143918304046"],"URL":"https:\/\/doi.org\/10.1016\/j.urolonc.2018.10.020","relation":{},"ISSN":["1078-1439"],"issn-type":[{"type":"print","value":"1078-1439"}],"subject":[],"published":{"date-parts":[[2019,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Serum testosterone level as possible predictive marker in androgen receptor axis-targeting agents and taxane chemotherapies for castration-resistant prostate cancer","name":"articletitle","label":"Article Title"},{"value":"Urologic Oncology: Seminars and Original Investigations","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.urolonc.2018.10.020","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}